Details

<p><b>Section I: Natural History of Chronic HCV</b></p><p><b> </b></p><p>Ch. 1- Epidemiology of Chronic HCV</p><p>            <i>Gary Davis</i></p><p>            <i><p>Ch. 2- Acute HCV      </p><p>            <i>Katja Deterding</i></p><p><i>            Heiner Wedemeyer</i></p><p><i>            Michael P. Manns</i></p><p><i> </i></p><p>Ch. 3- Assessing the Progression of Chronic HCV to Cirrhosis</p><p>            <i>Xavier Forns</i></p><p><i> </i></p><p>Ch. 4- Chronic HCV and Steatosis</p><p>            <i>Dawn McDowell Torres</i></p><p><i>            Stephen A. Harrison</i></p><p><i> </i></p><p>Ch. 5- Chronic HCV and Hepatocellular Carcinoma</p><p>            <i>Morris Sherman</i></p><p><i> </i></p><p>Ch. 6- Extrahepatic Manifestations of Chronic HCV</p><p>            <i>Antonio Craxi</i></p><p><i>            Vincenza Calvaruso</i></p><p><i> </i></p><p>Ch. 7- Chronic HCV and HIV Co-infection  </p><p>            <i>Patrick Ingiliz</i></p><p><i>            Maud Lemoine</i></p><p><i>            Yves Benhamou</i></p><p><i> </i></p><p>Ch. 8- Chronic HCV in Patients with Renal Disease</p><p>            <i>Paul Martin</i></p><p><i>            Fabrizio Fabrizi</i></p><p><i> </i></p><p>Ch. 9- Does Treatment Alter the Natural History of Chronic HCV</p><p>            <i>Bruce Bacon</i></p><p><i>            Fasiha Kanwal</i></p><p><i> </i></p><p><b>Section II: Treatment of Chronic HCV with Interferon Based Therapy</b></p><p> </p><p>Ch. 10- Treatment with Interferon and Ribavirin</p><p>            <i>Stuart Roberts</i></p><p><i>            William Kemp</i></p><p><i> </i></p><p>Ch. 11- Immune Modulators and Other Agents</p><p>            <i>Edgar D. Charles</i></p><p><i>            Ira M. Jacobson</i></p><p> </p><p>Ch. 12- Measuring HCV RNA and Assessing Virologic Response</p><p>            <i>Jean-Michel Pawlotsky</i></p><p><i>            </i></p><p>Ch. 13- Response Guided Therapy</p><p>            <i>Mitchell Shiffman</i></p><p><i> </i></p><p>Ch. 14- Managing the Side Effects of Therapy</p><p>            <i>Curtis Cooper</i></p><p> </p><p>Ch. 15- The Genetics of Virologic Response</p><p>            <i>Andrew J Muir</i></p><p><i>            Alison B. Jazwinski</i></p><p><i> </i></p><p>Ch. 16- Maintenance Therapy with Peginterferon</p><p>            <i>Nezem Afdahl</i></p><p><i>            Raza Malik</i></p><p><i> </i></p><p><i> </i></p><p><b>Section III: Anti-viral Therapy for Chronic HCV</b></p><p><i> </i></p><p>Ch. 17- Anti-viral Targets in HCV</p><p>            <i>Bernd Kronenberger</i></p><p><i>            Stefan Zeuzem</i></p><p><i> </i></p><p>Ch. 18- Mutations and the Development of Anti-viral Resistance</p><p>            <i>Geoffrey Dusheiko</i></p><p><i>            Anna Maria Geretti</i></p><p><i> </i></p><p>Ch. 19- Peginterferon, Ribavirin and Anti-viral Triple Therapy</p><p>            <i>Patrick Marcellin</i></p><p><i>            Nathalie Boyer</i></p><p><i>            Tarik Asselah</i></p><p><i> </i></p><p>Ch. 20- Treating Chronic HCV without Interferon and/or Ribavirin</p><p>            <i>Ed Gane</i></p><p><i> </i></p><p>Ch. 21- Maintenance Therapy with Oral Anti-viral Agents</p><p>            <i>Donald M. Jensen</i></p><p><i>            Andrew Aronsohn</i></p><p><i> </i></p><p><b>Section IV: Liver Transplantation for Chronic HCV</b></p><p><i> </i></p><p>Ch. 22- Natural History of Chronic HCV after Liver Transplantation          </p><p>            <i>Michael Charlton</i></p><p><i>            Bart J. Veldt</i></p><p><i> </i></p><p>Ch. 23- Use of HCV Positive Organs in Patients with and without Chronic HCV</p><p>            <i>Robert Brown</i></p><p><i>            Elizabeth C. Verna</i></p><p><i> </i></p><p>Ch. 24- Treating HCV Prior to Liver Transplantation</p><p>            <i>Greg Everson</i></p><p><i>            Alvaro Martinez-Camacho</i></p><p><i>            Brett E. Fortune</i></p><p><i> </i></p><p>Ch. 25- Treating HCV after Liver Transplantation</p><p>            <i>Sammy Saab</i></p><p><i>            Michael Chang</i></p><p><i>            Hubert Sung</i></p><p>            </p><p> </p><p> </p></i></p><p>Ch. 2- Acute HCV      </p><p>            <i>Katja Deterding</i></p><p><i>            Heiner Wedemeyer</i></p><p><i>            Michael P. Manns</i></p><p><i> </i></p><p>Ch. 3- Assessing the Progression of Chronic HCV to Cirrhosis</p><p>            <i>Xavier Forns</i></p><p><i> </i></p><p>Ch. 4- Chronic HCV and Steatosis</p><p>            <i>Dawn McDowell Torres</i></p><p><i>            Stephen A. Harrison</i></p><p><i> </i></p><p>Ch. 5- Chronic HCV and Hepatocellular Carcinoma</p><p>            <i>Morris Sherman</i></p><p><i> </i></p><p>Ch. 6- Extrahepatic Manifestations of Chronic HCV</p><p>            <i>Antonio Craxi</i></p><p><i>            Vincenza Calvaruso</i></p><p><i> </i></p><p>Ch. 7- Chronic HCV and HIV Co-infection  </p><p>            <i>Patrick Ingiliz</i></p><p><i>            Maud Lemoine</i></p><p><i>            Yves Benhamou</i></p><p><i> </i></p><p>Ch. 8- Chronic HCV in Patients with Renal Disease</p><p>            <i>Paul Martin</i></p><p><i>            Fabrizio Fabrizi</i></p><p><i> </i></p><p>Ch. 9- Does Treatment Alter the Natural History of Chronic HCV</p><p>            <i>Bruce Bacon</i></p><p><i>            Fasiha Kanwal</i></p><p><i> </i></p><p><b>Section II: Treatment of Chronic HCV with Interferon Based Therapy</b></p><p> </p><p>Ch. 10- Treatment with Interferon and Ribavirin</p><p>            <i>Stuart Roberts</i></p><p><i>            William Kemp</i></p><p><i> </i></p><p>Ch. 11- Immune Modulators and Other Agents</p><p>            <i>Edgar D. Charles</i></p><p><i>            Ira M. Jacobson</i></p><p> </p><p>Ch. 12- Measuring HCV RNA and Assessing Virologic Response</p><p>            <i>Jean-Michel Pawlotsky</i></p><p><i>            </i></p><p>Ch. 13- Response Guided Therapy</p><p>            <i>Mitchell Shiffman</i></p><p><i> </i></p><p>Ch. 14- Managing the Side Effects of Therapy</p><p>            <i>Curtis Cooper</i></p><p> </p><p>Ch. 15- The Genetics of Virologic Response</p><p>            <i>Andrew J Muir</i></p><p><i>            Alison B. Jazwinski</i></p><p><i> </i></p><p>Ch. 16- Maintenance Therapy with Peginterferon</p><p>            <i>Nezem Afdahl</i></p><p><i>            Raza Malik</i></p><p><i> </i></p><p><i> </i></p><p><b>Section III: Anti-viral Therapy for Chronic HCV</b></p><p><i> </i></p><p>Ch. 17- Anti-viral Targets in HCV</p><p>            <i>Bernd Kronenberger</i></p><p><i>            Stefan Zeuzem</i></p><p><i> </i></p><p>Ch. 18- Mutations and the Development of Anti-viral Resistance</p><p>            <i>Geoffrey Dusheiko</i></p><p><i>            Anna Maria Geretti</i></p><p><i> </i></p><p>Ch. 19- Peginterferon, Ribavirin and Anti-viral Triple Therapy</p><p>            <i>Patrick Marcellin</i></p><p><i>            Nathalie Boyer</i></p><p><i>            Tarik Asselah</i></p><p><i> </i></p><p>Ch. 20- Treating Chronic HCV without Interferon and/or Ribavirin</p><p>            <i>Ed Gane</i></p><p><i> </i></p><p>Ch. 21- Maintenance Therapy with Oral Anti-viral Agents</p><p>            <i>Donald M. Jensen</i></p><p><i>            Andrew Aronsohn</i></p><p><i> </i></p><p><b>Section IV: Liver Transplantation for Chronic HCV</b></p><p><i> </i></p><p>Ch. 22- Natural History of Chronic HCV after Liver Transplantation          </p><p>            <i>Michael Charlton</i></p><p><i>            Bart J. Veldt</i></p><p><i> </i></p><p>Ch. 23- Use of HCV Positive Organs in Patients with and without Chronic HCV</p><p>            <i>Robert Brown</i></p><p><i>            Elizabeth C. Verna</i></p><p><i> </i></p><p>Ch. 24- Treating HCV Prior to Liver Transplantation</p><p>            <i>Greg Everson</i></p><p><i>            Alvaro Martinez-Camacho</i></p><p><i>            Brett E. Fortune</i></p><p><i> </i></p><p>Ch. 25- Treating HCV after Liver Transplantation</p><p>            <i>Sammy Saab</i></p><p><i>            Michael Chang</i></p><p><i>            Hubert Sung</i></p><p>            </p><p> </p><p> </p><p><p>Ch. 2- Acute HCV      </p><p>            <i>Katja Deterding</i></p><p><i>            Heiner Wedemeyer</i></p><p><i>            Michael P. Manns</i></p><p><i> </i></p><p>Ch. 3- Assessing the Progression of Chronic HCV to Cirrhosis</p><p>            <i>Xavier Forns</i></p><p><i> </i></p><p>Ch. 4- Chronic HCV and Steatosis</p><p>            <i>Dawn McDowell Torres</i></p><p><i>            Stephen A. Harrison</i></p><p><i> </i></p><p>Ch. 5- Chronic HCV and Hepatocellular Carcinoma</p><p>            <i>Morris Sherman</i></p><p><i> </i></p><p>Ch. 6- Extrahepatic Manifestations of Chronic HCV</p><p>            <i>Antonio Craxi</i></p><p><i>            Vincenza Calvaruso</i></p><p><i> </i></p><p>Ch. 7- Chronic HCV and HIV Co-infection  </p><p>            <i>Patrick Ingiliz</i></p><p><i>            Maud Lemoine</i></p><p><i>            Yves Benhamou</i></p><p><i> </i></p><p>Ch. 8- Chronic HCV in Patients with Renal Disease</p><p>            <i>Paul Martin</i></p><p><i>            Fabrizio Fabrizi</i></p><p><i> </i></p><p>Ch. 9- Does Treatment Alter the Natural History of Chronic HCV</p><p>            <i>Bruce Bacon</i></p><p><i>            Fasiha Kanwal</i></p><p><i> </i></p><p><b>Section II: Treatment of Chronic HCV with Interferon Based Therapy</b></p><p> </p><p>Ch. 10- Treatment with Interferon and Ribavirin</p><p>            <i>Stuart Roberts</i></p><p><i>            William Kemp</i></p><p><i> </i></p><p>Ch. 11- Immune Modulators and Other Agents</p><p>            <i>Edgar D. Charles</i></p><p><i>            Ira M. Jacobson</i></p><p> </p><p>Ch. 12- Measuring HCV RNA and Assessing Virologic Response</p><p>            <i>Jean-Michel Pawlotsky</i></p><p><i>            </i></p><p>Ch. 13- Response Guided Therapy</p><p>            <i>Mitchell Shiffman</i></p><p><i> </i></p><p>Ch. 14- Managing the Side Effects of Therapy</p><p>            <i>Curtis Cooper</i></p><p> </p><p>Ch. 15- The Genetics of Virologic Response</p><p>            <i>Andrew J Muir</i></p><p><i>            Alison B. Jazwinski</i></p><p><i> </i></p><p>Ch. 16- Maintenance Therapy with Peginterferon</p><p>            <i>Nezem Afdahl</i></p><p><i>            Raza Malik</i></p><p><i> </i></p><p><i> </i></p><p><b>Section III: Anti-viral Therapy for Chronic HCV</b></p><p><i> </i></p><p>Ch. 17- Anti-viral Targets in HCV</p><p>            <i>Bernd Kronenberger</i></p><p><i>            Stefan Zeuzem</i></p><p><i> </i></p><p>Ch. 18- Mutations and the Development of Anti-viral Resistance</p><p>            <i>Geoffrey Dusheiko</i></p><p><i>            Anna Maria Geretti</i></p><p><i> </i></p><p>Ch. 19- Peginterferon, Ribavirin and Anti-viral Triple Therapy</p><p>            <i>Patrick Marcellin</i></p><p><i>            Nathalie Boyer</i></p><p><i>            Tarik Asselah</i></p><p><i> </i></p><p>Ch. 20- Treating Chronic HCV without Interferon and/or Ribavirin</p><p>            <i>Ed Gane</i></p><p><i> </i></p><p>Ch. 21- Maintenance Therapy with Oral Anti-viral Agents</p><p>            <i>Donald M. Jensen</i></p><p><i>            Andrew Aronsohn</i></p><p><i> </i></p><p><b>Section IV: Liver Transplantation for Chronic HCV</b></p><p><i> </i></p><p>Ch. 22- Natural History of Chronic HCV after Liver Transplantation          </p><p>            <i>Michael Charlton</i></p><p><i>            Bart J. Veldt</i></p><p><i> </i></p><p>Ch. 23- Use of HCV Positive Organs in Patients with and without Chronic HCV</p><p>            <i>Robert Brown</i></p><p><i>            Elizabeth C. Verna</i></p><p><i> </i></p><p>Ch. 24- Treating HCV Prior to Liver Transplantation</p><p>            <i>Greg Everson</i></p><p><i>            Alvaro Martinez-Camacho</i></p><p><i>            Brett E. Fortune</i></p><p><i> </i></p><p>Ch. 25- Treating HCV after Liver Transplantation</p><p>            <i>Sammy Saab</i></p><p><i>            Michael Chang</i></p><p><i>            Hubert Sung</i></p><p>            </p><p> </p><p> </p>

Mitchell L.  Shiffman, MD<br>Liver Institute of Virginia, Bon Secours Health System, Richmond, VA, USA

<i>Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future</i> documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. <i>Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future</i> is a valuable resource for all physicians caring for patients with chronic HCV.

<p>New anti-viral therapy explored</p><p>Outlines monumental advances in treatment</p><p>Presents current and future treatment options</p><p>Includes supplementary material: sn.pub/extras</p>

US